Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Ravaud

Showing results (431-440 of 457) with videos related to

Pageof 46
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|October 17, 2015
Long-Term Outcomes Among Participants in the WEGENT Trial of Remission-Maintenance Therapy for Granulomatosis With Polyangiitis (Wegener's) or Microscopic PolyangiitisXavier Puéchal, Christian Pagnoux, Élodie Perrodeau, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 6, 2017
Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors: A Randomized, Controlled TrialXavier Puéchal, Christian Pagnoux, Gabriel Baron, et al.
Annals of the Rheumatic Diseases|January 21, 2014
Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)Raphaèle Seror, Elke Theander, Johan G Brun, et al.
The Cochrane Database of Systematic Reviews|December 6, 2022
Efficacy and safety of COVID-19 vaccinesCarolina Graña, Lina Ghosn, Theodoros Evrenoglou, et al.
Annals of Internal Medicine|June 2, 2020
Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized TrialPierre Charles, Élodie Perrodeau, Maxime Samson, et al.
Arthritis and Rheumatism|May 28, 2010
Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registryBenjamin Terrier, Zahir Amoura, Philippe Ravaud, et al.
BMJ Medicine|November 3, 2023
Use of covid-19 convalescent plasma to treat patients admitted to hospital for covid-19 with or without underlying immunodeficiency: open label, randomised clinical trialKarine Lacombe, Thomas Hueso, Raphael Porcher, et al.
BMJ (Clinical Research Ed.)|May 16, 2020
Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care dataMatthieu Mahévas, Viet-Thi Tran, Mathilde Roumier, et al.
Annals of the Rheumatic Diseases|December 7, 2014
Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)Raphaèle Seror, Hendrika Bootsma, Alain Saraux, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 18, 2026
Accelerating real-world prediction and research in Alzheimer's: The M3AD studyMoïse Desvarieux, Tatjana Rundek, Habibul Ahsan, et al.
Pageof 46

Showing results (431-440 of 457) with videos related to

Sort By:
Pageof 46
Arthritis & Rheumatology (Hoboken, N.J.)|October 17, 2015
Long-Term Outcomes Among Participants in the WEGENT Trial of Remission-Maintenance Therapy for Granulomatosis With Polyangiitis (Wegener's) or Microscopic PolyangiitisXavier Puéchal, Christian Pagnoux, Élodie Perrodeau, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 6, 2017
Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors: A Randomized, Controlled TrialXavier Puéchal, Christian Pagnoux, Gabriel Baron, et al.
Annals of the Rheumatic Diseases|January 21, 2014
Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)Raphaèle Seror, Elke Theander, Johan G Brun, et al.
The Cochrane Database of Systematic Reviews|December 6, 2022
Efficacy and safety of COVID-19 vaccinesCarolina Graña, Lina Ghosn, Theodoros Evrenoglou, et al.
Annals of Internal Medicine|June 2, 2020
Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized TrialPierre Charles, Élodie Perrodeau, Maxime Samson, et al.
Arthritis and Rheumatism|May 28, 2010
Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registryBenjamin Terrier, Zahir Amoura, Philippe Ravaud, et al.
BMJ Medicine|November 3, 2023
Use of covid-19 convalescent plasma to treat patients admitted to hospital for covid-19 with or without underlying immunodeficiency: open label, randomised clinical trialKarine Lacombe, Thomas Hueso, Raphael Porcher, et al.
BMJ (Clinical Research Ed.)|May 16, 2020
Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care dataMatthieu Mahévas, Viet-Thi Tran, Mathilde Roumier, et al.
Annals of the Rheumatic Diseases|December 7, 2014
Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)Raphaèle Seror, Hendrika Bootsma, Alain Saraux, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 18, 2026
Accelerating real-world prediction and research in Alzheimer's: The M3AD studyMoïse Desvarieux, Tatjana Rundek, Habibul Ahsan, et al.
Pageof 46